Background
Adolescent girls and young women (AGYW) in East Africa face a high risk of HIV and other sexually transmitted infections (STIs). Delivery of HIV pre-exposure prophylaxis (PrEP) within pharmacies expands access, but few data exist on the burden of non-HIV STIs among AGYW in this setting. We assessed STI incidence among AGYW accessing PrEP at retail pharmacies in Kisumu, Kenya.
Methods
We evaluated Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in an ongoing cluster-randomized trial (NCT05467306) of PrEP delivery at 20 pharmacies. HIV-negative AGYW (ages 15–24) purchasing contraception (emergency contraception [EC], oral pills, injectables, implants, or condoms) were eligible. A subset was tested for CT/NG and TV using Xpert® nucleic acid amplification. Prevalence was defined as STI positivity at baseline; incident infections were new diagnoses at 10 months of follow-up among AGYW who did not have STIs at baseline. We used modified Poisson regression with cluster-robust standard errors to assess correlates of incident STIs, accounting for pharmacy-level clustering.
Results
As of May 2025, 751 AGYW were tested for CT/NG and 709 for TV. Median age was 20 years (IQR 18–22), and the most common contraception methods purchased were EC (39%), injectables (22%), and oral pills (19%); 15% purchased condoms only, and 5% purchased implants. PrEP acceptance at enrollment was 78% (82% oral pills, 18% vaginal ring). Baseline STI prevalence was 26%: 20% CT, 5% NG, and 7% TV; 5% had co-infections. Among AGYW STI-negative at baseline, 22 acquired an STI over 114.7 person-years (PY) for an incidence of 19.2 per 100 PY (95% CI: 12.0–29.0). Incidence rates were 16.9 for CT, 4.1 for NG, and 2.1 for TV per 100 PY. Incidence of any STI varied by contraceptive method: 26.6 for condoms only, 23.7 for EC, 18.7 per 100 PY for injectables, and 11.2 for oral pills; no incident STIs were observed among implant users. Unmarried AGYW had a higher risk of any incident STI compared to those who were married (incidence rate ratio=3.75, 95% CI 1.10-12.73, p=0.034). PrEP acceptance and younger age (<20 years vs. >=20 years) were not associated with STI incidence (p=0.939 and p=0.184, respectively).
Conclusions
AGYW accessing contraception and PrEP at pharmacies had high prevalence and incidence of STIs, especially CT. Integrating STI prevention and screening into pharmacy-based PrEP delivery would potentially be high-yield for AGYW in this setting.